Use Of Long-Acting Glp-1 Peptides - EP3689365
EP3689365
- Application Number
- EP20157813A
- Filing Date
- Jun 21, 2013
- Status
- Granted And Under Opposition
- Jul 4, 2025
- Grant Date
- Aug 6, 2025
- External Links
- Slate, Register, Google Patents
- Similar Patents facing opposition
Bibliography
The patent EP3689365B1 was granted to Novo Nordisk on Aug 6, 2025 following the initial filing on Jun 21, 2013 under the application number EP20157813A . The current legal status of the patent is Granted And Under Opposition.
Patent Summary
Patent Family New
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.
Date
Description
Get instant alerts for new documents